OCGN

Ocugen, Inc.

Phase 2 Confirmed

OCU410

Geographic Atrophy (late-stage dry AMD)

Resolved

173days ago

Phase 2 readout · Jan 15, 2026

What's at stake Phase 2 trial results for OCU410 in Geographic Atrophy (late-stage dry AMD) are due Jan 15, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 12h ago

“Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration”

Add to calendar Post on X Reddit

Provenance